...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Avian Diseases >Study of Efficacy and Replication of Recombinant Vector Vaccines by Using Turkey Herpesvirus Combined with Other Marek's Disease Vaccines
【24h】

Study of Efficacy and Replication of Recombinant Vector Vaccines by Using Turkey Herpesvirus Combined with Other Marek's Disease Vaccines

机译：用土耳其疱疹病毒结合其他马雷克疾病疫苗的重组载体疫苗的疗效和复制研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Several recombinant turkey herpesviruses (rHVTs) have been developed within the past decades, and they are now used commercially worldwide. In broiler chickens, rHVTs are usually administered alone, but in long-living birds they are used in combination with Marek's disease (MD) vaccines of other serotypes (i.e., CVI988). The objectives of this work were to 1) evaluate protection against MD conferred by HVT and two rHVTs when combined with CVI988 and 2) optimize the use of rHVT in combination with CVI988 to maximize replication of rHVT without compromising MD protection. Various vaccine protocols, all using rHVT or HVT at the recommended dose (RD), were evaluated. Protocols evaluated included in ovo vaccination with HVT+CVI988 or rHVT+CVI988 (using either the double dose [DD] or the RD of CVI988), day of age vaccination of rHVT-CVI988 at DD, and revaccination protocols using rHVT in ovo followed by CVI988 at DI) at day of age. Our results show that, when combined with CVI988, HVT and rHVTs confer a similar level of protection against MD (>90%) regardless of whether CVI988 was used at RD or at DD. However, the combination of rHVT with CVI988 at DD resulted in reduced replication rates of rHVT (60%-76% vs. 95%-100%). Our results show that such a negative effect could be avoided without jeopardizing MD protection by administering CVI988 at RD (if combined in ovo with rHVT) or administered rHVT first in ovo followed by CVI988 at DD at day of age.
机译：在过去的几十年里，几种重组土耳其疱疹病毒（RHVTS）已经发展起来，现在他们在商业上使用。在肉鸡鸡中，RHVT通常单独给药，但在长生鸟类中，它们与MAREK的疾病（MD）疫苗结合使用其他血清型（即，CVI988）。这项工作的目标是1）在与CVI988和2组合结合CVI988和2时，对HVT和两个rHVT赋予的MD的保护赋予保护，以及CVI988的使用，以最大化RHVT的复制而不会影响MD保护。评估各种疫苗协议，所有使用RHVT或HVT在推荐剂量（RD）中。用HVT + CVI988或RHVT + CVI988（使用CVI988的双剂量[DD]或RD），DD的rHVT-CVI988的年龄疫苗接种的当天，以及在OVO中使用RHVT的RHVACTINTION协议的当天接种CVI988在DI）在时代的日子。我们的研究结果表明，与CVI988结合时，无论CVI988是否在RD或DD中使用CVI988，HVT和RHVT会赋予MD（> 90％）相似的保护水平。然而，rhVT与DD的CVI988的组合导致RHVT的复制率降低（60％-76％与95％-100％）。我们的研究结果表明，通过在RD（如果在卵roVT中的卵ob中的CVI988施用CVI988或在ovo中施用RHVT，在DD的ovo中首先施用RHVT，可以避免这种负面影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号